TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$276 Million

Morphic Holding

Follow-on Offering

Bookrunner, May 2023

Morphic Holding

Morphic Holding or ("the Company's) is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology.